Physician profile
Susan E Pacheco
NPI 1982896304
$699.28
in general payments reported to CMS, 2019-2025
12 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.44 · 2023: $177 · 2024: $178 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $197.46 | 2023-2025 | |
| Pharming Healthcare, INC. | $122.45 | 2024-2025 | Ruconest |
| Genzyme Corporation | $99.82 | 2023-2025 | |
| Grifols USA, LLC | $72.58 | 2023-2025 | Xembify |
| Astrazeneca Pharmaceuticals LP | $43.49 | 2022-2024 | Tezspire |
| Csl Behring | $39.39 | 2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $29.03 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $27.66 | 2025 | Cuvitru |
| Tolmar, INC. | $19.80 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.89 | 2023 | Triptodur |
| Phadia US INC. | $15.25 | 2025 | Immunocap |
| Philips North America LLC | $14.46 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Pacheco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.